Tenderwize
Back to tender search

Discount Contract for Golimumab

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 343 days left·Open·Supplies
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-21 - Golimumab

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

No estimated value or volume information, making it difficult to assess potential business impact.

As an Open House discount contract, there is no guaranteed revenue; uptake depends on pharmacy substitution.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of pharmaceutical products containing the active substance Golimumab
  • Conclusion of discount contracts under § 130a Abs. 8 SGB V with standardized terms and conditions
Show full summary

Open House discount contract (Rabattvertrag) for the active substance Golimumab, administered by Techniker Krankenkasse (TK) on behalf of multiple German health insurance funds. Contract conclusion occurs under § 130a Abs. 8 SGB V with standardized terms, no exclusive rights, and a maximum duration of 12 months starting 01.08.2026, extendable by 12 months. This is an Open House procedure, not a public procurement subject to competition rules. No estimated value is provided.

Risks

No estimated value or volume information, making it difficult to assess potential business impact.

As an Open House discount contract, there is no guaranteed revenue; uptake depends on pharmacy substitution.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Pharmaceutical entrepreneur status (as per § 4 Abs. 18 AMG) for the offered medicinal product
  • Valid marketing authorization or entitlement to market the product under own name
  • Place of business in the AMG area, EU, or EEA

Requirements may be incomplete.

Award Criteria

Lot 1

Not applicable for Open House procedure; all qualifying participants are accepted.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Discount Contract for Golimumab

Discount contract for the active substance Golimumab under an Open House procedure. Contract concluded with all eligible pharmaceutical entrepreneurs who meet the qualification requirements.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Jul 2026 - Jul 2027

Category

Pharmaceutical products

Award Criteria

Not applicable for Open House procedure; all qualifying participants are accepted.

Deadline

Deadline Jul 30, 2027

Procurement Details

Publication date
07 Jun 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
389754-2026

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026

Aug 21

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9